UPC Stock Overview
Through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Universe Pharmaceuticals INC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.93 |
| 52 Week High | US$64.80 |
| 52 Week Low | US$1.71 |
| Beta | 1.54 |
| 11 Month Change | -64.16% |
| 3 Month Change | -96.05% |
| 1 Year Change | -87.63% |
| 33 Year Change | -99.06% |
| 5 Year Change | n/a |
| Change since IPO | -99.55% |
Recent News & Updates
Universe Pharmaceuticals INC (NASDAQ:UPC) Not Doing Enough For Some Investors As Its Shares Slump 44%
Nov 14
Why Investors Shouldn't Be Surprised By Universe Pharmaceuticals INC's (NASDAQ:UPC) 92% Share Price Plunge
Sep 27Universe Pharmaceuticals INC's (NASDAQ:UPC) 41% Price Boost Is Out Of Tune With Revenues
Jul 22Recent updates
Universe Pharmaceuticals INC (NASDAQ:UPC) Not Doing Enough For Some Investors As Its Shares Slump 44%
Nov 14Why Investors Shouldn't Be Surprised By Universe Pharmaceuticals INC's (NASDAQ:UPC) 92% Share Price Plunge
Sep 27Universe Pharmaceuticals INC's (NASDAQ:UPC) 41% Price Boost Is Out Of Tune With Revenues
Jul 22Universe Pharmaceuticals INC's (NASDAQ:UPC) Price Is Right But Growth Is Lacking After Shares Rocket 31%
May 22Universe Pharmaceuticals INC's (NASDAQ:UPC) Shares Bounce 27% But Its Business Still Trails The Industry
Apr 07Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 27%
Feb 07There's No Escaping Universe Pharmaceuticals INC's (NASDAQ:UPC) Muted Revenues Despite A 54% Share Price Rise
Dec 18Universe pharmaceuticals receives Nasdaq notification regarding minimum bid price deficiency
Jul 19Improved Earnings Required Before Universe Pharmaceuticals INC (NASDAQ:UPC) Shares Find Their Feet
Feb 21We Think That There Are Some Issues For Universe Pharmaceuticals (NASDAQ:UPC) Beyond Its Promising Earnings
Aug 10Shareholder Returns
| UPC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.6% | 1.6% | 2.2% |
| 1Y | -87.6% | 10.0% | 31.7% |
Return vs Industry: UPC underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: UPC underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| UPC volatility | |
|---|---|
| UPC Average Weekly Movement | 28.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: UPC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: UPC's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 225 | Gang Lai | www.universe-pharmacy.com |
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements.
Universe Pharmaceuticals INC Fundamentals Summary
| UPC fundamental statistics | |
|---|---|
| Market cap | US$2.82m |
| Earnings (TTM) | -US$18.55m |
| Revenue (TTM) | US$26.73m |
0.1x
P/S Ratio-0.2x
P/E RatioIs UPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UPC income statement (TTM) | |
|---|---|
| Revenue | US$26.73m |
| Cost of Revenue | US$19.17m |
| Gross Profit | US$7.56m |
| Other Expenses | US$26.11m |
| Earnings | -US$18.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.77 |
| Gross Margin | 28.27% |
| Net Profit Margin | -69.40% |
| Debt/Equity Ratio | 24.3% |
How did UPC perform over the long term?
See historical performance and comparison